My Tiny Feed

liberation.fr

EMA Approves Leqembi for Alzheimer's

The European Medicines Agency approves Leqembi, a new Alzheimer's treatment to reduce cognitive decline in early-stage patients. The drug targets amyloid plaques in the brain and has already received approvals in other countries.

Read original article in French

French

France

HealthTreatmentAlzheimer'sMedical BreakthroughCognitive DeclineDrug Approval

European Medicines Agency (Ema)EisaiBiogenUk's Medicines And Healthcare Products Regulatory Agency

What is Leqembi and what is its purpose?: The European Medicines Agency (EMA) approved Leqembi, a new treatment to reduce cognitive decline in Alzheimer's patients. It's for patients in the early stages of the disease, not those with advanced Alzheimer's.
How does Leqembi work, and how is it administered?: Leqembi, developed by Eisai and Biogen, works by reducing amyloid plaques in the brain, which are associated with memory loss in Alzheimer's patients. It's administered intravenously every two weeks.
In which countries has Leqembi already been approved?: Leqembi has already been approved in the United States, Japan, and China for patients in the early stages of Alzheimer's. The UK's Medicines and Healthcare products Regulatory Agency also approved it.
What is still unknown about Alzheimer's disease despite this breakthrough?: While Leqembi offers hope, the exact cause of Alzheimer's disease remains poorly understood. Further research is needed to fully understand the disease and develop more effective treatments.
Why did the EMA initially reject Leqembi, and what changed their decision?: The EMA initially rejected Leqembi due to concerns about serious side effects like brain bleeding. However, after a re-examination, they determined the benefits outweighed the risks for a specific patient group.

Jan 23, 01:10

Microplastics Linked to Brain Blood Clots, Raising Dementia and Stroke Risks

A Peking University study reveals microplastics in the brain trigger immune responses, causing blood clots that may lead to stroke, depression, and possibly dementia; further research is needed.

Jan 23, 04:13

Child Mental Health Admissions to Acute Wards in England Surge by 65%

A study shows a 65% rise in English children's mental health admissions to general acute wards from 2012-2022, reaching 39,925 in 2022; this increase, particularly among girls aged 11-15 (112.8%), strains hospital resources and staff, highlighting underlying societal issues beyond the COVID-19 pandemic.

Jan 23, 01:10

Rare Gene Mutation Linked to Late-Onset Alzheimer's

A study of an Italian family with six members affected by late-onset Alzheimer's disease reveals a rare mutation in the GRIN2C gene as a probable cause, offering a significant advancement in understanding the disease's genetic basis.

Jan 23, 01:10

Danish Medical Data Breach Exposes 130,000 Patient Records

A data breach at a Danish medical practice group exposed the sensitive information of 130,000 patients, including names, addresses, national identification numbers, and treatment protocols, nearly a month after the initial cyberattack, sparking public outrage over the delayed notification.